A PHASE III MULTICENTER, RANDOMIZED STUDY COMPARING CONSOLIDATION WITH (90)YTTRIUM-LABELED IBRITUMOMAB TIUXETAN (ZEVALIN®) RADIOIMMUNOTHERAPY VS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA (FL) AGED 18-65 YEARS - FIL_FLAZ-12

Start Date08 Oct 2013

Sponsor / Collaborator-

NCT01811368

/ Unknown statusPhase 2IIT

Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma

This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma. Giving rituximab, antithymocyte globulin, and total-lymphoid irradiation (TLI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. Also, radiolabeled monoclonal antibodies, such as ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving rituximab, antithymocyte globulin, and TLI before the transplant together with cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. Giving a radiolabeled monoclonal antibody before a donor peripheral blood stem cell transplant may be an effective treatment for non-Hodgkin lymphoma.

Start Date12 Mar 2013

Sponsor / Collaborator

University of California, Davis

[+1]

100 Clinical Results associated with Ibritumomab Tiuxetan

100 Translational Medicine associated with Ibritumomab Tiuxetan

100 Patents (Medical) associated with Ibritumomab Tiuxetan

473

Literatures (Medical) associated with Ibritumomab Tiuxetan

01 Jul 2024·Seminars in Nuclear Medicine

The Rebirth of Radioimmunotherapy of Non-Hodgkin Lymphoma: The Phoenix of Nuclear Medicine?

Review

Author: Kahl, Brad ; Wahl, Richard L

In Greek mythology, The Phoenix is an immortal bird that dies, but then achieves new life by rising from the ashes of its predecessor. Radioimmunotherapy (RIT) of B-cell Non-Hodgkin lymphoma (NHL) is a field which once began to fly high-with FDA approval of the anti-CD20 RITs Zevalin® and Bexxar® in 2002 and 2003 respectively, as safe and effective therapies of NHL. However, despite their therapeutic efficacy, Bexxar® was withdrawn from the market by the manufacturer in 2014 due to limited commercial demand and Zevalin® has had very limited to no availability of late. I-131 rituximab is used to a limited extent in Australia, India and other countries, as well. But has RIT of NHL been (perhaps prematurely) left for dead by many? Given the current great clinical and commercial interest in radiopharmaceutical therapies of cancer, notably PSMA and SSTR targeting agents in prostate and neuroendocrine cancers, can radioimmunotherapy of NHL-like the mythical Phoenix-now rise from its ashes in an even better form to fly higher, faster, farther and longer than before?

04 Apr 2024·The Oncologist

A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma

Review

Author: Tuscano, Joseph ; Durando, Michael ; Gopal, Ajay K ; Persky, Daniel

AbstractPurposeThe clinical efficacy of anti-CD20 radioimmunotherapy (RIT) is due to a combination of extracellular mechanisms involving immune-mediated cytotoxicity, and intracellular mechanisms related to inhibition of CD20 signaling and DNA damage from ionizing radiation. In 2002, the first RIT was approved by the U.S. Food and Drug Administration for the treatment of patients with indolent B-cell follicular non-Hodgkin lymphoma (NHL). The 2 approved agents, 90 Y-ibritumomab tiuxetan (90Y-IT, Zevalin, Acrotech Biopharma) and 131 I-tositumomab (131-IT, Bexxar, GlaxoSmithKline) both target CD20. The aim of this study was to review the clinical applications and supporting clinical trial data of anti-CD20 RIT for lymphoma.MethodsA review of published articles and abstracts on the clinical efficacy and safety of 90Y-IT and iodine I 131 tositumomab was performed.ResultsThe clinical efficacy and safety of anti-CD20 RIT have been demonstrated in numerous clinical trials and case series. Agents have produced significant responses in patients with follicular NHLs and in off-label applications. Importantly, RIT has demonstrated promising findings in high-risk lymphomas and heavily pretreated and refractory patient populations. Associated toxicity profiles are noted as tolerable, acceptable, and most often reversible.ConclusionsIn the 2 decades since its approval, anti-CD20 RIT continues to demonstrate efficacy, particularly with a proportion of patients maintaining long-term remissions. The combination of prolonged efficacy, tolerability, and treatment convenience makes RIT a reasonable alternative to other systemic therapies. It is recommended that further research on RIT should focus on biomarkers of long-term response, pretargeting, and sequencing of RIT in the treatment course.

23 Feb 2024·Leukemia & Lymphoma

The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma

Article

Author: Witzig, Thomas E. ; Wiseman, Gregory A. ; Ansell, Stephen ; Laoruangroj, Chonlada ; Atherton, Pamela J. ; Schumacher, Peyton ; Feldman, Andrew L.

Patients with asymptomatic follicular lymphoma (AFL) are candidates for observation or immunotherapy. Given the effectiveness of radiation therapy in FL, another option is 90Yttrium-ibritumomab tiuxetan radioimmunotherapy (RIT). We conducted a trial where untreated AFL patients were randomized to rituximab 375 mg/m2 weekly × 4 or rituximab 250 mg/m² days 1, 8, and 0.4 mCi/kg (maximum 32 mCi) of RIT day 8. Twenty patients were enrolled before the study was halted due to unavailability of RIT. The ORR for rituximab and RIT were 90% and 80%, respectively; the CR rate at 6 months was 30% and 60%, respectively. After a median follow-up of 67 months, eight patients have progressed-three in the rituximab arm and five in the RIT arm and five have required systemic therapy. All patients remain alive. Both agents are highly active for AFL. The 1-week treatment with RIT and sparing of T-cells make combination therapy with newer agents attractive.

News (Medical) associated with Ibritumomab Tiuxetan

02 Oct 2024

·www.pharmaceutical-technology.com

Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec

Radiopharmaceuticals have taken off in recent years, with several high-profile deals signed by big pharma. Image credit: Shutterstock / Creative_Bird. Amid the boom in the radiopharmaceutical space, peptide-based therapeutics could be set to outmanoeuvre antibody-based counterparts, according to WuXi AppTec ’s discovery services vice-president Dr Dave Madge. “We see a lot of potential to reposition a lot of existing radiotherapeutics that are antibody derived to peptide-based radiotherapeutics,” said Madge while speaking at the ELRIG Drug Discovery conference in London, UK, from 2 to 3 October. Antibody-based radiopharmaceuticals have been widely employed in cancer therapy. However, only two have been approved by the US Food and Drug Administration (FDA) – Spectrum Pharmaceutical’s Zevalin (90Y-ibritumomab tiuxetan) and GSK ’s Bexxar (131I-tositumomab). Although their high specificity and affinity for target antigens make antibodies a robust carrier for radionuclide delivery, peptide-based alternatives offer other advantages, including tissue penetration and low toxicity. “A lot of work in this area is moving on from antibody-derived radiotherapeutics and identifying peptide analogs,” Madge said. See Also: ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapy Whilst WuXi’s speaker did not elucidate on the company’s plans in the space, hints can be gathered from its recent financial activity. In January 2024, the Chinese biotech announced the commission of two new peptide manufacturing plants – one at its Changzhou facility and another at a new site in Taixing, China. The expansion boosts WuXi’s solid-phase peptide synthesis total reactor volume to 32,000l in response “to a surging global demand for peptide therapeutics”, the company said during the announcement. WuXi offers “advanced radiopharmaceutical solutions to support drug development”, according to its website. “We’ve seen many high-profile deals in the last three or four years, such as partnerships and acquisitions…this area is gaining ground and there’s massive potential for accelerating cancer therapy,” Madge explained. Several big pharma companies have made the radiopharma jump over the past few years, with Bristol Myers Squibb (BMS), Novartis , and Eli Lilly all signing $4.2bn , $1.75bn , and $1.4bn acquisition deals respectively. Madge said the desire to combine radiodiagnostics and radiotherapeutics within the industry has been a key driver of the space’s growth. Known as theranostic radiopharmaceuticals, this approach uses radioactive drugs that combine diagnostic imaging and therapeutic activity to treat diseases. Last month, Telix Pharmaceuticals paid $230m upfront to acquire US-based radioisotope manufacturer RLS Radiopharmacies to expand its manufacturing footprint in the US. However, for WuXi, matching the global demand for this area could be curbed by the US BIOSECURE Act . This bill, which passed the House of Representatives last month , would prevent US companies from working with certain Chinese biotech life science companies – WuXi AppTec is one of those implicated. The bill’s future now lies with the Senate, with current ties between drugmakers and Chinse contractors looking precarious. WuXi called the bill “a pre-emptive and unjustified designation without due process that the company strongly objects to” in a statement. “We firmly believe that WuXi AppTec has not posed, does not pose, and will not pose a security risk to the US or any other country and it has not been subject to any sanction by the US Government agencies,” the biotech added.

Drug ApprovalAcquisition

17 Sep 2024

·www.biopharmadive.com

‘Really exciting times’: One biotech’s view of radiopharma’s boom

As far as cancer treatments go, radiopharmaceuticals are conceptually simple. After all, radioactive isotopes are very good at killing cancer cells. And as targeting technology improves, large pharma companies are paying closer attention to the drug field and the many smaller biotechnology firms within it.This radio-renaissance belies the long history of radiation-based drugs, the idea for which has been around for more than half a century, said Jack Hoppin, CEO of Ratio Therapeutics, one of those small biotechs.Its not a novel concept to put a radioisotope into patients, Hoppin said, describing research into the radioisotope iodine-131 in the 1950s.Decades later in the early 2000s, GSKs Bexxar and Idec Pharmaceuticals Zevalin both won approvals to treat lymphoma, but their use never took off due to logistical and other issues. While radioisotopes became commonplace in diagnostic imaging, the current boom in radiopharmaceuticals was brought on by two drugs now owned by Novartis: Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer.There have been a couple other successes in the space, but those are the two driving forces that caught everyones eye, said Hoppin. When a buyer like Novartis steps in and starts building infrastructure, and oncologists are willing to prescribe and treat directly with these drugs, it builds momentum.Ratio is still early in its own development journey. But backed by another pharma giant, Bristol Myers Squibb, the company has a front row seat to the fields rapid expansion.I think youll see these drugs evolve in the way that antibody-drug conjugates have said Hoppin. It took time to adopt and come to fruition, but were now in an era where companies are looking for fit-for-purpose molecules for radioligand therapy and the characteristics required to be successful.Merging fieldsOne of the challenges in developing radiopharmaceuticals is balancing the drugs potency with their safety. The isotope the drugs contain must be linked securely enough to a targeting compound that it reaches the target tumors, but loosely enough that it can be deposited upon arrival.To get that balance right requires more than just biology and chemistry, said Hoppin, who holds a Ph.D. in mathematics. For example, understanding the way radioactive isotopes actinium-225 in Ratios case populate into a tumor is as much a math problem as it is biological.People in pharmaceutical sciences underestimate nuclear medicine, and people in nuclear medicine underestimate pharmaceutical sciences, said Hoppin. We try to acknowledge that youre only as good as the weakest disciplinarian within your group.Ratio uses actinium-225 with a combination of targeting and linking platforms to ensure a calculated dose for its treatments, one of which is close to entering Phase 1 testing.While biotechnology advances can come in seemingly overnight breakthroughs, Hopping credits the steady accumulation of better targets and biomarkers for the growth in therapeutic radiopharmaceuticals.There wasnt a clear-cut smoking gun that changed the market, he said. [It was] more an evolution of medicinal chemistry and biomarker technology to image these agents faster and more quantitatively.Building a marketRatio is one of more than a dozen small- to mid-sized startups exploring radiopharmaceuticals. Acquisitions by large pharma companies have boosted the field, encouraging the formation of new companies and funding for those already established.Bristol Myers Squibb announced a $4.1 billion acquisition of RayzeBio at the end of last year. That same week, Eli Lilly completed a $1.4 billion purchase of Point Biopharma. Both companies have radiopharmaceutical candidates in clinical trials.Then this year, AstraZeneca bought Fusion Pharmaceuticals for $2.4 billion, continuing the dealmaking trend. There were 86 licensing, partnering or acquisition deals in the radiopharmaceuticals field over the last five years, according to a Nature report, with the number of deals nearly tripling between 2021 and 2022.There are still challenges in the field, as Hoppin can attest, from manufacturing of radioactive materials to supply chain and storage. But the future looks bright.Some of these things cant be instantly solved, but looking out a decade, there are going to be multiple approvals and really exciting times, Hoppin said. '

AcquisitionRadiation Therapy

16 Sep 2024

·www.prnewswire.com

Expanding the Bispecific Antibody Market from CAR-Ts to Drive Follicular Lymphoma's Future | DelveInsight

The competition in follicular lymphoma is rapidly intensifying, with three CAR-T therapies and three bispecific antibodies now approved for relapsed or refractory patients. As both classes of treatments expand, the battle for dominance in this market is growing, with each therapy offering unique advantages in accessibility, efficacy, and safety profiles, setting the stage for a dynamic shift in treatment strategies. LAS VEGAS, Sept. 16, 2024 /PRNewswire/ -- Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL) that develops from B-lymphocytes and is generally slow-growing or indolent. This subtype represents 20–30% of all NHL cases. While follicular lymphoma typically progresses slowly, there are instances where it can grow more rapidly. Treatment options for follicular lymphoma include, chemotherapy, radiation therapy, immunotherapy, stem cell transplantation, CAR T-cell therapy, and bispecific-antibodies. For those in the early stages of the disease (Ann Arbor stages I or II), treatment may involve radiation therapy alone or in combination with chemotherapy. Patients with advanced follicular lymphoma are typically treated initially with a combination of chemotherapy and anti-CD20 antibodies, a method known as chemoimmunotherapy. The most commonly used antibodies are RITUXAN (rituximab) and GAZYVA (obinutuzumab), which specifically target tumor cells associated with follicular lymphoma. In older patients who do not have organ dysfunction, treatment with rituximab alone may be an option. Other therapies like ZEVALIN (yttrium-90 ibritumomab tiuxetan), TAZVERIK (tazemetostat), REVLIMID (lenalidomide), and others are approved for the treatment of follicular lymphoma. CAR T-cell therapies are becoming increasingly significant in treating follicular lymphoma. YESCARTA, a CD19-directed genetically modified autologous T-cell therapy, became the first CAR-T to be approved for follicular lymphoma by the US FDA in March 2021. Before the approval of YESCARTA, BREYANZI was approved in February 2021 for Grade 3B follicular lymphoma that accounts for about 5-10% of all follicular lymphoma cases. Later in April 2022 it was approved by the European commission. In May 2024 BREYANZI was approved for the treatment of relapsed/refractory follicular lymphoma who have received two or more prior lines of systemic therapy and provided sustained clinical benefit with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months. In May 2022, Novartis announced that the European Commission approved KYMRIAH (tisagenlecleucel) for adult patients with relapsed/refractory follicular lymphoma who have undergone two or more systemic therapies. This approval represents the third indication for KYMRIAH, making it the first CAR-T cell therapy sanctioned in Europe for such patients, including those with relapsed/refractory follicular lymphoma Grades 1, 2, and 3A. Additionally, in May 2022, the US FDA granted approval for KYMRIAH for the same patient group. Currently, autologous CAR-T therapies are the only ones approved, but the emerging pipeline predominantly comprises autologous CAR-Ts alongside a growing number of allogeneic CAR-T therapies. Allogeneic CAR-T, a newer term, refers to donor-derived therapies offering several advantages over autologous treatments. These off-the-shelf therapies are readily available, eliminating the need to modify patient cells either at a central manufacturing site or at the point of care. Even though the reimbursement of CAR-T therapies represents a challenge for healthcare providers, insurers, and government agencies, they have successfully reached the majority of the markets by considering the patient pool demand. While determining the cost and reimbursement, various factors, such as pharmacoeconomic analysis and outcome-based responses, as well as the added value to society, have been evaluated. The CAR T-cell-related toxicity, such as the cytokine-release syndrome and neurotoxicity, remain important potential complications of this therapy. Second generation CAR T-cell therapies are emerging with more safety and efficacy to overcome these limitations. If these limitations have been overcome, these are going to be the potential drivers of the market. After CAR-T approval companies focused on developing alternative therapies to overcome CAR-Ts limitations. LUNSUMIO became the first bispecific antibody to get approval for adult patients with relapsed/refractory follicular lymphoma who have undergone two or more lines of systemic treatment in June 2022 in Europe. Later in December 2022, the US FDA approved it for the same indication. This was the game changing step toward a brighter future for follicular lymphoma patients. Bispecific antibodies are ready to use therapies and safer treatment options than CAR-Ts. In 2023, LUNSUMIO captured USD 55 million in revenue in the United States for follicular lymphoma. In the United States, AbbVie and Genmab's epcoritamab, marketed as EPKINLY, first gained FDA approval in May 2023 for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This was followed by its approval for follicular lymphoma in June 2024. With the recent FDA authorization for relapsed/refractory follicular lymphoma, along with expected approvals and launches in international markets, EPKINLY is poised to see revenue growth in the coming quarters. Its strong performance in treating relapsed/refractory DLBCL suggests it could achieve similar success in follicular lymphoma. LUNSUMIO now faces competition in the European market for follicular lymphoma, as on August 19, 2024, the European Commission granted approval for the expanded use of AbbVie and Genmab's bispecific antibody, TEPKINLY (epcoritamab), for treating adults with relapsed/refractory follicular lymphoma. The study showed an overall response rate of 83% and a complete response rate of 63%, with the median response duration being 21.4 months. Just after TEPKINLY approval in Europe, Regeneron's ORDSPONO (odronextamab) a CD20 x CD3 bispecific antibody approved by European Commission on August 26, 2024 for the treatment of adult patients with relapsed/refractory follicular lymphoma or relapsed/refractory DLBCL, after two or more lines of systemic therapy. After this approval, ORDSPONO becomes the first off-the-shelf option that can be administered in the out-patient setting. In March 2024, the US FDA declined approval for odronextamab for treating follicular lymphoma and DLBCL. The agency issued two complete response letters concerning the biologics license application (BLA) for odronextamab in relapsed/refractory follicular lymphoma and DLBCL after two or more lines of systemic therapy. The denial was tied to the enrollment status of confirmatory trials assessing the drug. Importantly, there were no concerns raised about odronextamab's efficacy, safety, trial design, labeling, or manufacturing. Both EPKINLY, LUNSUMIO, and ORDSPONO are off-the-shelf therapies, offering greater accessibility compared to CD19 CAR-T treatments. These drugs will compete not only with each other but also with CAR-T therapies to secure a substantial portion of the follicular lymphoma market. Learn more about the FDA-approved follicular lymphoma drugs @ Drugs for Follicular Lymphoma Treatment A new class has also emerged for the treatment of follicular lymphoma, i.e., Bruton tyrosine kinase (BTK) inhibitors. In November 2023, BeiGene received approval from the European Commission for BRUKINSA (zanubrutinib) to treat relapsed/refractory follicular lymphoma. Later in March 2024, the US FDA approved BRUKINSA for the same indication. BRUKINSA is the first and only BTK inhibitor approved for this condition. To know more about follicular lymphoma treatment options, visit @ New Treatment for Follicular Lymphoma The follicular lymphoma pipeline is robust with so many companies working in the domain. Various potential therapies that are projected to enter during the forecast period include AbbVie's IMBRUVICA, Xynomic Pharmaceuticals' Abexinostat, Pfizer PF-06821497, Incyte's Parsaclisib, Bristol-Myers Squibb's Nivolumab, and others. Discover which therapies are expected to grab major follicular lymphoma market share @ Follicular Lymphoma Market Report IMBRUVICA (ibrutinib) is an anti-cancer medication available in various forms, including hard gelatin capsules, tablets, film-coated tablets, and oral suspension. It is being developed by AbbVie and is currently undergoing Phase III trials for follicular lymphoma. This study aims to determine if adding ibrutinib to the treatment will extend progression-free survival (PFS) compared to using rituximab alone in patients with newly diagnosed follicular lymphoma. Xynomic Pharmaceuticals is developing Abexinostat for treating follicular lymphoma. The company is currently testing this investigational drug in a Phase II clinical trial involving patients with relapsed/refractory follicular lymphoma who have received at least three prior therapies. The US FDA has granted Abexinostat fast-track designation for this use. In June 2021, Xynomic completed a short-form merger with Xu-Nuo Pharma in a "Going Private" transaction. Post-merger, Xu-Nuo Pharma will continue Xynomic's business as its main focus. Discover more about drugs for follicular lymphoma in development @ Follicular Lymphoma Clinical Trials The anticipated launch of these emerging therapies for follicular lymphoma are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the follicular lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for follicular lymphoma is expected to grow from USD 1.4 billion in 2020 with a significant CAGR by 2034. This growth can be attributed to the introduction of upcoming therapies and the rise in the increasing incidence of follicular lymphoma. DelveInsight's latest published market report titled as Follicular Lymphoma Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the follicular lymphoma country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The follicular lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of Follicular Lymphoma Risk-specific Incident Cases of Follicular Lymphoma Stage-specific Incident Cases of Follicular Lymphoma Mutation-specific Incident Cases of Follicular Lymphoma Transplant Eligible and Ineligible Patient Pool of Follicular Lymphoma Refractory/Relapsed Incident Cases of Follicular Lymphoma The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM follicular lymphoma market. Highlights include: 11-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis up to 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this follicular lymphoma market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the follicular lymphoma market. Also, stay abreast of the mitigating factors to improve your market position in the follicular lymphoma therapeutic space. Related Reports Follicular Lymphoma Pipeline Follicular Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key follicular lymphoma companies, including Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc, Allogene Therapeutics, MEI Pharma, Innovent Biologics, among others. Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics, among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key DLBCL companies, including AbbVie, Genmab, Merck, Roche, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2ImmunotherapyDrug ApprovalFast TrackPhase 3

100 Deals associated with Ibritumomab Tiuxetan

External Link

KEGG	Wiki	ATC	Drug Bank
D04489	Ibritumomab Tiuxetan	V10XX02	DB00078

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Mantle-Cell Lymphoma	Japan	Mundipharma KK	25 Jan 2008
B-Cell Lymphoma	Liechtenstein	Ceft Biopharma s.r.o.	16 Jan 2004
B-Cell Lymphoma	Norway	Ceft Biopharma s.r.o.	16 Jan 2004
B-Cell Lymphoma	European Union	Ceft Biopharma s.r.o.	16 Jan 2004
B-Cell Lymphoma	Iceland	Ceft Biopharma s.r.o.	16 Jan 2004
Follicular Lymphoma	Iceland	Ceft Biopharma s.r.o.	16 Jan 2004
Follicular Lymphoma	Norway	Ceft Biopharma s.r.o.	16 Jan 2004
Follicular Lymphoma	Liechtenstein	Ceft Biopharma s.r.o.	16 Jan 2004
Follicular Lymphoma	European Union	Ceft Biopharma s.r.o.	16 Jan 2004
Non-Hodgkin Lymphoma	United States	Spectrum Pharmaceuticals, Inc.	19 Feb 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Follicular Lymphoma	Phase 1	Netherlands	Bayer AG	01 Aug 2001
Follicular Lymphoma	Phase 1	France	Bayer AG	01 Aug 2001
Follicular Lymphoma	Phase 1	Switzerland	Bayer AG	01 Aug 2001
Follicular Lymphoma	Phase 1	Portugal	Bayer AG	01 Aug 2001
Follicular Lymphoma	Phase 1	Italy	Bayer AG	01 Aug 2001
Follicular Lymphoma	Preclinical	Netherlands	Bayer AG	01 Aug 2001
Follicular Lymphoma	Preclinical	Switzerland	Bayer AG	01 Aug 2001
Follicular Lymphoma	Preclinical	France	Bayer AG	01 Aug 2001
Follicular Lymphoma	Preclinical	Italy	Bayer AG	01 Aug 2001
Follicular Lymphoma	Preclinical	Portugal	Bayer AG	01 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00290511 (CTgov)	Phase 2	Follicular Lymphoma	49	Fludarabine+Zevalin+Mitoxantrone+dexamethasone+Rituximab	(czxnysnlgs) = qgxieefynw ccbagesdvx (wfuxhuqboy, ktbstgcapb - bqlpzhtwsj) View more	-	22 Apr 2022
NCT00772655 (Pubmed \| Ann Hematol)	Phase 2	Follicular Lymphoma First line	-	90-yttrium-ibritumomab tiuxetan	mbiganskgi(vqkjlejoqe) = ksrxuexozn sgnifbidyl (pczpqvodqc ) View more	Positive	12 Feb 2022
NCT00322218 (CTgov)	Phase 3	Diffuse Large B-Cell Lymphoma	68	Zevalin	rowafpefjo(eourrkpawy) = bqffejczoo xwgtzetisb (kwguysendj, lhuyghwjrp - pvtcsiuyua) View more	-	19 Jan 2022
Tandem Meetings ASTCT and CIBMTR2021	Phase 2	Large B-cell lymphoma CD20+	20	90 Y-Ibritumomab tiuxetan	(gpqvnhwlhq) = guaqoyhhbj zvfbigugio (tcycasfnzd, 54 - 92) View more	Positive	01 Mar 2021
NCT00493467 (CTgov)	Phase 2	Indolent Non-Hodgkin Lymphoma	31	Ibritumomab Tiuxetan (Zevalin)+Rituximab	(hinllyjisf) = pybdszljxz mkmgbwtjvl (frjaoflldi, zaymvxyhpt - fihsygefph) View more	-	01 Sep 2020
NCT00491491 (CTgov)	Phase 3	Diffuse large B-cell lymphoma recurrent	60	BEAM chemotherapy+ibritumomab tiuxetan (Z-BEAM)	(whizsbyngu) = dvidbewkps goduqskntt (bpjwnykklc, lqjzdcmvud - wgiyahccra) View more	-	31 Aug 2020
NCT00491491 (CTgov)	Phase 3	Diffuse large B-cell lymphoma recurrent	60	BEAM chemotherapy (Standard BEAM)	(whizsbyngu) = fqvtzizzyr goduqskntt (bpjwnykklc, kxaezjprcf - blqxuspvgk) View more	-	31 Aug 2020
NCT01490723 (CTgov)	Phase 2	Chronic Lymphocytic Leukemia \| Lymphoma	20	Planar Scintigraphy Imaging+Bendamustine+Fludarabine+111In Ibritumomab+thymoglobulin+G-CSF+Tacrolimus+Mycophenolate+Rituximab+Methotrexate	(invghbaixe) = gbiznbvemx mbuanpwjev (qskbsjwymk, szpeyyetlr - qhvukewqai) View more	-	05 May 2020
ASCO_SITC2020	Not Applicable	Non-Hodgkin Lymphoma CD20	171	Zevalin	xwvnhhhhry(ngqicyeuae) = sdbmljcwzk idlueoynbs (jqmvscspdc ) View more	Positive	06 Feb 2020
NCT00582166 (CTgov)	Phase 2	Indolent Non-Hodgkin Lymphoma	18	Zevalin+Rituximab	(levsbdyaui) = ptnydqcdsr hjfxqpisnc (lnywtnxgkn, uqeymgyiaw - nudkocqslw) View more	-	13 Jul 2018
GOTEL (ASCO2018)	Phase 2	Follicular Lymphoma Consolidation	-	Yttrium-90 ibritumomab tiuxetan	(rpzpjvjlsd) = ywizrieawb ipstdmkjsd (kiibuhxbiv ) View more	Positive	01 Jun 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis